MAPT and Alzheimer disease: Hence, they suggest that chronic reduction of BDNF does not exacerbate the development of Aβ and Tau pathology and instead suggest the reduced BDNF levels found in AD patients are a consequence of these pathologies (Castello et al., 2012).